Raymond James Financial Inc. Invests $14.90 Million in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Raymond James Financial Inc. purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 161,708 shares of the medical instruments supplier's stock, valued at approximately $14,900,000. Raymond James Financial Inc. owned about 0.72% of LeMaitre Vascular at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its position in shares of LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 117 shares during the last quarter. KBC Group NV lifted its holdings in LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares during the period. Huntington National Bank grew its stake in LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares during the period. Finally, Empowered Funds LLC purchased a new stake in shares of LeMaitre Vascular during the 4th quarter valued at $150,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 1.8 %

Shares of NASDAQ LMAT opened at $84.72 on Tuesday. The company has a market cap of $1.91 billion, a P/E ratio of 46.30, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $62.40 and a 52 week high of $109.58. The business has a 50-day simple moving average of $87.62 and a two-hundred day simple moving average of $93.47.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.94%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio (DPR) is presently 41.24%.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.79% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on LMAT shares. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Finally, Lake Street Capital boosted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of "Moderate Buy" and a consensus target price of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.